These results demonstrate that the STL001 is a universal inhibitor of FOXM1 in cancer cells, also it is 25–50 times more efficient in reducing the cellular FOXM1 activity in solid cancer as compared to its parental compound STL427944 [5]. The gene discussed is FOXM1; the disease is cancer.